KRAS‐mutant cancers, especially G12D‐dominated PDAC, exhibit an immunologically cold TME and heightened resistance to anti‐PD‐1 immunotherapy, presenting an intriguing avenue for investigating innovative combinatorial strategies with immunomodulators.[42] Inhibition of CDK9 has recently been recognized as a promising strategy for epigenetic immunosensitization, suggesting its potential impact on awakening the “hot” tumor immunity. Here, KRAS is linked to neoplasm.